Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TRACY W DOBBS

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1104826148
CMS profile
185806
Location
KNOXVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$5,171.57

189 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,048.99 185
Consulting Fee $2,086.00 1
Education $36.58 3

By paying entity

PY2020 · entire year · sorted by reported total

Page 4 of 4; records 151–189 of 189 matching records. This page contains 39 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TRACY W DOBBS

NPI 1104826148 · CMS profile ID 185806

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

KNOXVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–189 of 189 matching records. This page contains 39 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104826148?year=2020&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TRACY W DOBBS, NPI 1104826148, CMS profile ID 185806. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–189 of 189 matching records. This page contains 39 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104826148?year=2020&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). TRACY W DOBBS, NPI 1104826148, CMS profile ID 185806. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–189 of 189 matching records. This page contains 39 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104826148?year=2020&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
TRACY W DOBBS, NPI 1104826148, CMS profile ID 185806, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–189 of 189 matching records. This page contains 39 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1104826148?year=2020&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

189 matching records · $5,171.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 189 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–189 of 189.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $12.1403/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743597501 CMS
Seagen Inc. $10.2503/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732443449 CMS
Bayer HealthCare Pharmaceuticals Inc. $14.3903/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713644371 CMS
GENZYME CORPORATION $11.9103/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744078217 CMS
AMAG Pharmaceuticals, Inc. $13.3803/03/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753006679 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.1003/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747329987 CMS
Amgen Inc. $26.2502/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741340817 CMS
Incyte Corporation $18.4302/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745801615 CMS
PFIZER INC. $10.8402/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743599659 CMS
Incyte Corporation $18.9302/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745801611 CMS
AbbVie Inc. $12.7802/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721754829 CMS
PFIZER INC. $12.3902/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743597443 CMS
EMD Serono, Inc. $17.3402/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751269069 CMS
Amgen Inc. $37.9502/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741449737 CMS
Merck Sharp & Dohme Corporation $16.0902/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747713631 CMS
Merck Sharp & Dohme Corporation $15.5102/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747744699 CMS
Genentech USA, Inc. $19.2502/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743125325 CMS
Exelixis Inc. $11.6002/06/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737174975 CMS
E.R. Squibb & Sons, L.L.C. $11.8002/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727825685 CMS
TOLMAR Pharmaceuticals, Inc. $18.1902/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721465743 CMS
E.R. Squibb & Sons, L.L.C. $12.3901/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727825675 CMS
Amgen Inc. $17.8101/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741340797 CMS
AstraZeneca Pharmaceuticals LP $19.3701/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735775151 CMS
PFIZER INC. $14.0901/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743597207 CMS
GENZYME CORPORATION $15.3901/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744078195 CMS
ARRAY BIOPHARMA INC $12.4801/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743738893 CMS
ARRAY BIOPHARMA INC $1.1901/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743738895 CMS
Astellas Pharma US Inc $14.5301/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718316925 CMS
Merck Sharp & Dohme Corporation $13.8701/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747664653 CMS
Seagen Inc. $13.6601/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732443385 CMS
Merck Sharp & Dohme Corporation $15.7101/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747697369 CMS
Novartis Pharmaceuticals Corporation $18.0601/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725695561 CMS
Merck Sharp & Dohme Corporation $17.4701/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747701825 CMS
E.R. Squibb & Sons, L.L.C. $12.3501/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727825659 CMS
Agios Pharmaceuticals, Inc. $11.4801/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751963369 CMS
Seagen Inc. $8.0701/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732443381 CMS
PFIZER INC. $7.5701/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743601159 CMS
Bayer HealthCare Pharmaceuticals Inc. $23.4401/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713624797 CMS
AstraZeneca Pharmaceuticals LP $18.9801/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735922383 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,943.13 195
PY2020 $5,171.57 189
PY2021 $3,121.69 193
PY2022 $4,033.51 226
PY2023 $3,676.21 211
PY2024 $3,467.54 155
PY2025 $3,652.58 160

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $129,641.37 30
PY2024 Principal investigator $25,302.00 20
PY2023 Principal investigator $24,049.00 7
PY2022 Principal investigator $198,622.00 47
PY2021 Principal investigator $23,375.88 10
PY2020 Principal investigator $70,030.72 6
PY2019 Principal investigator $39,178.04 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

30 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 12/31/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744602
Principal investigator 1 Janssen Research & Development, LLC $4,734.00 12/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175327787
Principal investigator 1 PFIZER INC. $356.50 12/15/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228714360
Principal investigator 1 PFIZER INC. $23,590.88 12/15/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228714362
Principal investigator 1 PFIZER INC. $19,908.70 12/15/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228715039
Principal investigator 1 PFIZER INC. $461.25 12/15/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228715041
Principal investigator 1 PFIZER INC. $2,987.04 12/15/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228715043
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 11/30/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744600
Principal investigator 1 Janssen Research & Development, LLC $4,200.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175327731
Principal investigator 1 Janssen Research & Development, LLC $4,500.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175329263
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175329312
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175329402
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175329801
Principal investigator 1 Janssen Research & Development, LLC $2,684.00 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175327341
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,725.00 10/31/2025 Non-covered Recipient Entity
TENNESSEE CANCER SPECIALISTS, PLLC
a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer No dispute reported 06/30/2026 1185540009
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 10/31/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744598
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 09/30/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744576
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 09/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175329221
Principal investigator 1 Janssen Research & Development, LLC $17,000.00 09/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175329679
Principal investigator 1 Janssen Research & Development, LLC $11,719.00 09/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175327062
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 08/31/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744578
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 07/31/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744580
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 06/30/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744582
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 05/31/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744584
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 04/30/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744586
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 03/31/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744588
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 02/28/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744590
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $975.00 02/28/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744592
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 02/28/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744594
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5,000.00 01/31/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744596